343 related articles for article (PubMed ID: 37026045)
1. Mesoporous silica nanoparticles: Their potential as drug delivery carriers and nanoscavengers in Alzheimer's and Parkinson's diseases.
Attia MS; Yahya A; Monaem NA; Sabry SA
Saudi Pharm J; 2023 Mar; 31(3):417-432. PubMed ID: 37026045
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's Disease and Parkinson's Disease: A Review of Current Treatment Adopting a Nanotechnology Approach.
Trompetero A; Gordillo A; Del Pilar MC; Cristina VM; Bustos Cruz RH
Curr Pharm Des; 2018; 24(1):22-45. PubMed ID: 28847307
[TBL] [Abstract][Full Text] [Related]
3. Emerging Perspectives on Gene Therapy Delivery for Neurodegenerative and Neuromuscular Disorders.
Gomez Limia C; Baird M; Schwartz M; Saxena S; Meyer K; Wein N
J Pers Med; 2022 Nov; 12(12):. PubMed ID: 36556200
[TBL] [Abstract][Full Text] [Related]
4. Nanotheranostic agents for neurodegenerative diseases.
Padmanabhan P; Palanivel M; Kumar A; Máthé D; Radda GK; Lim KL; Gulyás B
Emerg Top Life Sci; 2020 Dec; 4(6):645-675. PubMed ID: 33320185
[TBL] [Abstract][Full Text] [Related]
5. Current Small Molecule-Based Medicinal Chemistry Approaches for Neurodegeneration Therapeutics.
Sanghai N; Vuong B; Burak Berk A; Afridi MSK; Tranmer GK
ChemMedChem; 2024 May; 19(9):e202300705. PubMed ID: 38329887
[TBL] [Abstract][Full Text] [Related]
6. Bridging Size and Charge Effects of Mesoporous Silica Nanoparticles for Crossing the Blood-Brain Barrier.
Chen YP; Chou CM; Chang TY; Ting H; Dembélé J; Chu YT; Liu TP; Changou CA; Liu CW; Chen CT
Front Chem; 2022; 10():931584. PubMed ID: 35880111
[TBL] [Abstract][Full Text] [Related]
7. Novel Gene Therapy Approaches for Targeting Neurodegenerative Disorders: Focusing on Delivering Neurotrophic Genes.
Kumari S; Kamiya A; Karnik SS; Rohilla S; Dubey SK; Taliyan R
Mol Neurobiol; 2024 Jun; ():. PubMed ID: 38856793
[TBL] [Abstract][Full Text] [Related]
8. L-Dopa release from mesoporous silica nanoparticles engineered through the concept of drug-structure-directing agents for Parkinson's disease.
Morales V; McConnell J; Pérez-Garnes M; Almendro N; Sanz R; García-Muñoz RA
J Mater Chem B; 2021 May; 9(20):4178-4189. PubMed ID: 33989370
[TBL] [Abstract][Full Text] [Related]
9. Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases.
Seo MW; Park TE
Biomed Eng Lett; 2021 Aug; 11(3):211-216. PubMed ID: 34350048
[TBL] [Abstract][Full Text] [Related]
10. Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease).
Spuch C; Navarro C
J Drug Deliv; 2011; 2011():469679. PubMed ID: 22203906
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticles-based delivery system and its potentials in treating central nervous system disorders.
Liu T; Xie Q; Dong Z; Peng Q
Nanotechnology; 2022 Aug; 33(45):. PubMed ID: 35917704
[TBL] [Abstract][Full Text] [Related]
12. Mesoporous Silica Nanoparticles as Carriers for Biomolecules in Cancer Therapy.
Küçüktürkmen B; Rosenholm JM
Adv Exp Med Biol; 2021; 1295():99-120. PubMed ID: 33543457
[TBL] [Abstract][Full Text] [Related]
13. Polysorbate-coated mesoporous silica nanoparticles as an efficient carrier for improved rivastigmine brain delivery.
Fateh Basharzad S; Hamidi M; Maleki A; Karami Z; Mohamadpour H; Reza Saghatchi Zanjani M
Brain Res; 2022 Apr; 1781():147786. PubMed ID: 35041841
[TBL] [Abstract][Full Text] [Related]
14. Advances in regulating physicochemical properties of mesoporous silica nanocarriers to overcome biological barriers.
Wang Y; Gou K; Guo X; Ke J; Li S; Li H
Acta Biomater; 2021 Mar; 123():72-92. PubMed ID: 33454385
[TBL] [Abstract][Full Text] [Related]
15. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
Teixeira MI; Lopes CM; Amaral MH; Costa PC
Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
[TBL] [Abstract][Full Text] [Related]
16. A Review on Recent Technologies and Patents on Silica Nanoparticles for Cancer Treatment and Diagnosis.
Gupta A; Kushwaha SS; Mishra A
Recent Pat Drug Deliv Formul; 2020; 14(2):126-144. PubMed ID: 32928094
[TBL] [Abstract][Full Text] [Related]
17. Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting.
Agrawal M; Saraf S; Saraf S; Dubey SK; Puri A; Patel RJ; Ajazuddin ; Ravichandiran V; Murty US; Alexander A
J Control Release; 2020 May; 321():372-415. PubMed ID: 32061621
[TBL] [Abstract][Full Text] [Related]
18. Exploiting mesoporous silica, silver and gold nanoparticles for neurodegenerative diseases treatment.
Ribeiro TC; Sábio RM; Carvalho GC; Fonseca-Santos B; Chorilli M
Int J Pharm; 2022 Aug; 624():121978. PubMed ID: 35792231
[TBL] [Abstract][Full Text] [Related]
19. Gold nanoparticle-capped mesoporous silica-based H
Yang L; Yin T; Liu Y; Sun J; Zhou Y; Liu J
Acta Biomater; 2016 Dec; 46():177-190. PubMed ID: 27619837
[TBL] [Abstract][Full Text] [Related]
20. Research Progress of Nanocarriers for the Treatment of Alzheimer's Disease.
Li L; Zhang J; Huang X; Du J; Tu Z; Wu H; Liu X; Yuan M
Curr Pharm Des; 2023; 29(2):95-115. PubMed ID: 36529920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
